KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kura Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$9.36+0.28 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $831.68M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
98.0%
87M of 89M shares
Institutional holders
220
28 new, 25 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
2 buys · 40 sales
Net sold $1.49M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bvf Partners L P/Il | 8,677,018 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Aaron Cowen | 8,575,422 | 9.70% | 13G (passive) amendment | Jun 30, 2026 |
| Suvretta Capital Management, LLC | 7,561,000 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 6,329,050 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| Bvf Inc/Il | 5,912,554 | 7.50% | 13G (passive) | Jan 27, 2025 |
| Steven Boyd | 4,936,000 | 5.67% | 13G (passive) amendment | Dec 31, 2025 |
| State Street Corporation | 4,931,090 | 5.70% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 4,428,812 | 5.01% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KURA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,509,233 | 11.81% | $115.29M | +871,702 | 0.00% |
| Suvretta Capital Management, LLC | 8,575,422 | 9.64% | $94.07M | – | 1.72% |
| Bvf Inc/Il | 8,445,769 | 9.49% | $92.65M | – | 2.37% |
| State Street Corp | 5,329,208 | 5.99% | $58.46M | +817,317 | 0.00% |
| Vanguard Capital Management LLC | 3,916,164 | 4.40% | $42.96M | +130,479 | 0.00% |
| Armistice Capital, LLC | 3,678,000 | 4.13% | $40.35M | −58,000 | 0.49% |
| Aqr Capital Management LLC | 3,126,727 | 3.51% | $34.30M | +1,002,247 | 0.01% |
| Goldman Sachs Group Inc | 2,265,171 | 2.55% | $24.85M | +831,700 | 0.00% |
| Geode Capital Management, LLC | 2,229,958 | 2.51% | $24.47M | +195,682 | 0.00% |
| Alethea Capital Management, LLC | 2,167,938 | 2.44% | $23.78M | +638,569 | 9.85% |
| Prosight Management, LP | 2,021,964 | 2.27% | $22.18M | −1,334,736 | 3.82% |
| Deep Track Capital, LP | 1,978,565 | 2.22% | $21.70M | −664,977 | 0.32% |
| Renaissance Technologies LLC | 1,663,765 | 1.87% | $18.25M | +81,197 | 0.03% |
| Arrowstreet Capital, Limited Partnership | 1,410,275 | 1.59% | $15.47M | New | 0.01% |
| Vanguard Portfolio Management LLC | 1,329,941 | 1.49% | $14.59M | +99,139 | 0.00% |
| Nan Fung Trinity (Hk) Ltd | 1,174,880 | 1.32% | $12.89M | +110,000 | 1.27% |
| Qube Research & Technologies Ltd | 1,169,884 | 1.32% | $12.83M | −466,849 | 0.01% |
| Dimensional Fund Advisors LP | 1,169,189 | 1.31% | $12.83M | −256,756 | 0.00% |
| Bank Of America Corp /De/ | 1,160,921 | 1.30% | $12.74M | −69,210 | 0.00% |
| Morgan Stanley | 1,160,310 | 1.30% | $12.73M | −3,667 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 220 | 87M | 98.0% | 28 / 92 | 64 / 25 | 12M | 9M |
| Q1 2026 | 222 | 84M | 94.9% | 37 / 69 | 83 / 27 | 15M | 11M |
| Q4 2025 | 215 | 85M | 96.0% | 44 / 90 | 55 / 27 | 12M | 10M |
| Q3 2025 | 200 | 84M | 94.3% | 43 / 76 | 51 / 24 | 14M | 12M |
| Q2 2025 | 182 | 82M | 92.3% | 29 / 83 | 45 / 29 | 13M | 12M |
| Q1 2025 | 183 | 80M | 90.4% | 36 / 62 | 56 / 36 | 15M | 13M |
| Q4 2024 | 185 | 79M | 88.6% | 48 / 70 | 36 / 41 | 24M | 28M |
| Q3 2024 | 179 | 83M | 93.1% | 22 / 63 | 53 / 16 | 14M | 6M |
| Q2 2024 | 174 | 81M | 90.9% | 29 / 55 | 61 / 19 | 6M | 9M |
| Q1 2024 | 165 | 84M | 94.3% | 40 / 55 | 47 / 15 | 12M | 9M |
| Q4 2023 | 140 | 81M | 90.6% | 22 / 49 | 43 / 15 | 10M | 5M |
| Q3 2023 | 133 | 75M | 84.7% | 9 / 64 | 34 / 24 | 6M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KURA | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,105,747 | 3.49% | $34.07M | 0.32% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,799,338 | 3.15% | $30.71M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,210,614 | 2.48% | $24.25M | 0.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,026,943 | 1.15% | $11.27M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 928,988 | 1.04% | $8.37M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 785,096 | 0.88% | $8.61M | 0.06% | Jun 30, 2026 |
| iShares Biotechnology ETF | 606,113 | 0.68% | $6.65M | 0.07% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 564,979 | 0.64% | $5.76M | 0.11% | May 29, 2026 |
| Fidelity Extended Market Index Fund | 451,547 | 0.51% | $4.61M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 414,458 | 0.47% | $4.23M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 413,820 | 0.47% | $4.22M | 0.02% | May 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 300,321 | 0.34% | $3.29M | 0.11% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 268,920 | 0.30% | $2.42M | 0.01% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 263,839 | 0.30% | $2.89M | 0.05% | Jun 30, 2026 |
| Vanguard Explorer Fund | 245,051 | 0.28% | $2.21M | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Troy Edward Wilson | President and CEO, Director | 1,214,650 | 1.37% | Aug 24, 2026 |
| Thomas James Doyle | SVP, Finance & Accounting | 142,928 | 0.16% | Sep 29, 2026 |
| Kathleen Ford | Chief Operating Officer | 142,986 | 0.16% | Sep 29, 2026 |
| Brian T. Powl | Chief Commercial Officer | 136,819 | 0.15% | Sep 29, 2026 |
| Teresa Brophy Bair | Chief Legal Officer | 187,002 | 0.21% | Sep 29, 2026 |
| Mollie Leoni | Chief Medical Officer | 141,095 | 0.16% | Sep 29, 2026 |
| Francis Burrows | Chief Scientific Officer | 63,053 | 0.07% | Sep 25, 2026 |
| Jennifer Fulk | Chief Financial Officer | – | – | Sep 10, 2026 |
| Helen Louise Collins | Director | – | – | Jun 4, 2026 |
| Diane L. Parks | Director | – | – | Jun 4, 2026 |
| Faheem Hasnain | Director | 23,983 | 0.03% | Jun 4, 2026 |
| Mary T. Szela | Director | – | – | Jun 4, 2026 |
| Thomas Malley | Director | 149,557 | 0.17% | Jun 4, 2026 |
| Michael Vasconcelles | Director | – | – | Jun 4, 2026 |
| Carol Schafer | Director | – | – | Jun 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian T. Powl Chief Commercial Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −15,430 | $10.75 | $165.87K | 136,819 |
| Kathleen Ford Chief Operating Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −3,668 | $10.75 | $39.43K | 142,986 |
| Mollie Leoni Chief Medical Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −28,802 | $10.75 | $309.62K | 141,095 |
| Teresa Brophy Bair Chief Legal Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −8,442 | $10.50 | $88.64K | 187,002 |
| Brian T. Powl Chief Commercial Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −8,000 | $10.56 | $84.48K | 152,249 |
| Brian T. Powl Chief Commercial Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −9,020 | $10.50 | $94.71K | 160,249 |
| Kathleen Ford Chief Operating Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −6,906 | $10.50 | $72.51K | 146,654 |
| Thomas James Doyle SVP, Finance & Accounting | Sep 28, 2026 | Sale | −4,607 | $10.50 | $48.37K | 142,428 |
| Mollie Leoni Chief Medical Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −12,448 | $10.50 | $130.70K | 169,897 |
| Francis Burrows Chief Scientific Officer | Sep 24, 2026 | Option exercise | +30,000 | $6.15 | $184.50K | 63,053 |
| Francis Burrows Chief Scientific Officer | Sep 24, 2026 | Sale | −20,726 | $10.83 | $224.46K | 42,327 |
| Troy Edward Wilson President and CEO, Director | Aug 24, 2026 | Buy | +100,000 | $12.39 | $1.24M | 479,194 |
| Brian T. Powl Chief Commercial Officer | Aug 21, 2026 | Sale(10b5-1 plan) | −4,345 | $11.89 | $51.66K | 169,269 |
| Teresa Brophy Bair Chief Legal Officer | Aug 19, 2026 | Sale(10b5-1 plan) | −31,487 | $12.63 | $397.68K | 195,444 |
| Troy Edward Wilson President and CEO, Director | Aug 17, 2026 | Buy | +100,000 | $11.12 | $1.11M | 379,194 |
| Mollie Leoni Chief Medical Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −84,929 | $9.82 | $834.00K | 182,345 |
| Brian T. Powl Chief Commercial Officer | May 21, 2026 | Sale(10b5-1 plan) | −10,000 | $11.00 | $110.00K | 173,614 |
| Brian T. Powl Chief Commercial Officer | May 19, 2026 | Sale(10b5-1 plan) | −339 | $9.21 | $3.12K | 183,614 |
| Kathleen Ford Chief Operating Officer | May 19, 2026 | Sale(10b5-1 plan) | −2,257 | $9.08 | $20.49K | 153,560 |
| Teresa Brophy Bair Chief Legal Officer | May 18, 2026 | Sale(10b5-1 plan) | −2,256 | $9.38 | $21.16K | 226,931 |
| Troy Edward Wilson President and CEO, Director | Mar 23, 2026 | Option exercise | +6,103 | $6.15 | $37.53K | 435,456 |
| Thomas Malley Director | Mar 18, 2026 | Option exercise | +10,000 | $3.12 | $31.20K | 10,000 |
| Francis Burrows Chief Scientific Officer | Jan 27, 2026 | Sale | −1,311 | $8.46 | $11.09K | 32,424 |
| Kathleen Ford Chief Operating Officer | Jan 27, 2026 | Sale | −1,813 | $8.46 | $15.34K | 153,560 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −2,233 | $8.46 | $18.89K | 269,566 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −3,655 | $8.46 | $30.92K | 271,799 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −951 | $8.46 | $8.05K | 268,615 |
| Mollie Leoni Chief Medical Officer | Jan 27, 2026 | Sale | −1,341 | $8.46 | $11.34K | 267,274 |
| Teresa Brophy Bair Chief Legal Officer | Jan 27, 2026 | Sale | −4,096 | $8.46 | $34.65K | 234,043 |
| Teresa Brophy Bair Chief Legal Officer | Jan 27, 2026 | Sale | −2,335 | $8.46 | $19.75K | 231,708 |
| Teresa Brophy Bair Chief Legal Officer | Jan 27, 2026 | Sale | −4,777 | $8.46 | $40.41K | 226,931 |
| Brian T. Powl Chief Commercial Officer | Jan 27, 2026 | Sale | −4,842 | $8.46 | $40.96K | 184,847 |
| Brian T. Powl Chief Commercial Officer | Jan 27, 2026 | Sale | −1,572 | $8.46 | $13.30K | 183,275 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −2,226 | $8.46 | $18.83K | 150,083 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −881 | $8.46 | $7.45K | 145,167 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −2,226 | $8.46 | $18.83K | 146,048 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −695 | $8.46 | $5.88K | 148,274 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 27, 2026 | Sale | −1,114 | $8.46 | $9.42K | 148,969 |
| Teresa Brophy Bair Chief Legal Officer | Jan 2, 2026 | Award | +50,000 | – | – | 238,139 |
| Thomas James Doyle SVP, Finance & Accounting | Jan 2, 2026 | Award | +21,250 | – | – | 152,309 |
| Mollie Leoni Chief Medical Officer | Jan 2, 2026 | Award | +50,000 | – | – | 275,454 |
| Kathleen Ford Chief Operating Officer | Jan 2, 2026 | Award | +50,000 | – | – | 155,373 |
| Brian T. Powl Chief Commercial Officer | Jan 2, 2026 | Award | +50,000 | – | – | 189,689 |
| Francis Burrows Chief Scientific Officer | Dec 18, 2025 | Option exercise | +35,000 | $4.80 | $168.00K | 57,461 |
| Francis Burrows Chief Scientific Officer | Dec 18, 2025 | Sale | −23,726 | $9.78 | $232.04K | 33,735 |
| Faheem Hasnain Director | Dec 9, 2025 | Sale(10b5-1 plan) | −10,000 | $10.98 | $109.80K | 23,983 |
| Faheem Hasnain Director | Dec 9, 2025 | Option exercise | +10,000 | $3.12 | $31.20K | 33,983 |
| Mollie Leoni Chief Medical Officer | Nov 14, 2025 | Sale | −15,485 | $11.18 | $173.12K | 225,454 |
| Kathleen Ford Chief Operating Officer | Nov 14, 2025 | Sale(10b5-1 plan) | −6,902 | $11.18 | $77.16K | 105,373 |
| Teresa Brophy Bair Chief Legal Officer | Nov 14, 2025 | Sale(10b5-1 plan) | −8,804 | $11.18 | $98.43K | 188,139 |
| Brian T. Powl Chief Commercial Officer | Nov 14, 2025 | Sale | −8,887 | $11.18 | $99.36K | 139,689 |
| Thomas James Doyle SVP, Finance & Accounting | Nov 14, 2025 | Sale | −4,539 | $11.18 | $50.75K | 130,257 |
| Mollie Leoni Chief Medical Officer | Nov 13, 2025 | Award | +82,500 | – | – | 240,939 |
| Troy Edward Wilson President and CEO, Director | Nov 13, 2025 | Award | +182,500 | – | – | 429,353 |
| Kathleen Ford Chief Operating Officer | Nov 13, 2025 | Award | +48,900 | – | – | 112,275 |
| Teresa Brophy Bair Chief Legal Officer | Nov 13, 2025 | Award | +48,900 | – | – | 196,943 |
| Brian T. Powl Chief Commercial Officer | Nov 13, 2025 | Award | +48,900 | – | – | 148,576 |
| Thomas James Doyle SVP, Finance & Accounting | Nov 13, 2025 | Award | +24,967 | – | – | 134,796 |
| Teresa Brophy Bair Chief Legal Officer | Sep 29, 2025 | Sale(10b5-1 plan) | −8,805 | $8.94 | $78.72K | 148,043 |
| Troy Edward Wilson President and CEO, Director | Sep 29, 2025 | Sale | −36,615 | $8.94 | $327.34K | 246,853 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Leoni Mollie Officer | Sep 29, 2026 | 28,802 | $305.59K | Sep 29, 2026 | Performance Stock Units |
| Powl Brian Officer | Sep 29, 2026 | 15,430 | $163.71K | Sep 29, 2026 | Restricted Stock Units |
| Ford Kathleen Officer | Sep 29, 2026 | 3,668 | $38.92K | Sep 29, 2026 | Performance Stock Units |
| Kathleen Ford Officer | Sep 28, 2026 | 6,906 | $74.31K | Sep 28, 2026 | PSU |
| Brian T. Powl Officer | Sep 28, 2026 | 9,020 | $97.06K | Sep 28, 2026 | RSU |
| Powl Brian Officer | Sep 28, 2026 | 8,000 | $86.08K | Sep 28, 2026 | Restricted Stock Units |
| Thomas James Doyle Officer | Sep 28, 2026 | 4,607 | $49.57K | Sep 28, 2026 | PSU |
| Teresa Brophy Bair Officer | Sep 28, 2026 | 8,442 | $90.84K | Sep 28, 2026 | PSU |
| Mollie Leoni Officer | Sep 28, 2026 | 12,448 | $133.94K | Sep 28, 2026 | PSU |
| J. Burrows Francis Officer | Sep 24, 2026 | 20,726 | $224.51K | Sep 24, 2026 | Stock Option Exercise |
| Powl Brian Officer | Aug 21, 2026 | 4,345 | $50.88K | Aug 21, 2026 | Restricted Stock Units |
| Bair Teresa Officer | Aug 19, 2026 | 31,487 | $388.23K | Aug 19, 2026 | Restricted Stock Units |
| Vanessa Leoni Mollie Officer | Jun 18, 2026 | 84,929 | $812.77K | Jun 18, 2026 | Restricted Stock Units |
| Powl Brian Officer | May 21, 2026 | 10,000 | $103.40K | May 21, 2026 | Restricted Stock Units |
| Powl Brian Officer | May 19, 2026 | 339 | $3.12K | May 19, 2026 | Employee Stock Purchase Plan |